Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
08:16am, Thursday, 06'th Nov 2025
Haemonetics (HAE) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.12 per share a year ago.
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart
08:00am, Thursday, 06'th Nov 2025
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced posit
– Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on pediatric patients and their caregivers – – ORLADEYO oral granules demonstrated early an
Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
06:00am, Thursday, 06'th Nov 2025
Financial release and supplemental presentation accessible online BOSTON , Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fisc
Victory Sycamore Small Company Opportunity Fund Q3 2025 Top Contributors And Detractors
02:56pm, Thursday, 30'th Oct 2025
Supply has tightened over the past few years, setting NAND up for strong demand and pricing amid constrained supply. TSEM produces Silicon Photonics chips that are used in optical transceivers, which
Critical Comparison: VAREX IMAGING (NASDAQ:VREX) vs. Haemonetics (NYSE:HAE)
02:36am, Sunday, 26'th Oct 2025
VAREX IMAGING (NASDAQ: VREX - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the s
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
07:00am, Thursday, 23'rd Oct 2025
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Mee
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
07:00am, Tuesday, 14'th Oct 2025
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio –
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025
04:05pm, Thursday, 09'th Oct 2025
BOSTON , Oct. 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, No
Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial
08:00am, Thursday, 02'nd Oct 2025
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that
Mark Penn to Headline Harvard Alumni Entrepreneurs Startup World Cup Regional
08:31am, Tuesday, 02'nd Sep 2025
Strategist, author of Microtrends , Harvard alumnus shares insights on unicorn trends, global shifts, and investor sentiment BOSTON , Sept. 2, 2025 /PRNewswire/ -- Harvard Alumni Entrepreneurs (HAE)
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
12:44pm, Monday, 11'th Aug 2025
Haemonetics Corporation remains a high-quality blood-management franchise with strong TEG and plasma software moats, but recent growth has paused due to portfolio shifts and competition. Q1 FY2026 res
Understanding Haemonetics (HAE) Reliance on International Revenue
10:21am, Monday, 11'th Aug 2025
Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript
10:53pm, Saturday, 09'th Aug 2025
Haemonetics Corporation (NYSE:HAE ) Q1 2026 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christopher A. Simon - CEO, President & Director James C.
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
09:14am, Friday, 08'th Aug 2025
Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday.
